These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 26760311)

  • 1. Brivaracetam for the treatment of epilepsy.
    Klein P; Tyrlikova I; Brazdil M; Rektor I
    Expert Opin Pharmacother; 2016; 17(2):283-95. PubMed ID: 26760311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy.
    Klein P; Bourikas D
    Adv Ther; 2024 Jul; 41(7):2682-2699. PubMed ID: 38811492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of brivaracetam: a new drug to treat epilepsy.
    Milovanović JR; Janković SM; Pejčić A; Milosavljević M; Opančina V; Radonjić V; Protrka Z; Kostić M
    Expert Opin Pharmacother; 2017 Sep; 18(13):1381-1389. PubMed ID: 28737479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brivaracetam: First Global Approval.
    Markham A
    Drugs; 2016 Mar; 76(4):517-22. PubMed ID: 26899665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brivaracetam: new compound approved for the treatment of epilepsy.
    Zaccara G
    Drugs Today (Barc); 2016 Apr; 52(4):219-27. PubMed ID: 27252986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brivaracetam: An Adjunctive Treatment for Partial-Onset Seizures.
    Kappes JA; Hayes WJ; Strain JD; Farver DK
    J Clin Pharmacol; 2017 Jul; 57(7):811-817. PubMed ID: 28394442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
    Gillard M; Fuks B; Leclercq K; Matagne A
    Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.
    Matagne A; Margineanu DG; Kenda B; Michel P; Klitgaard H
    Br J Pharmacol; 2008 Aug; 154(8):1662-71. PubMed ID: 18500360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in the management of partial-onset epilepsy: role of brivaracetam.
    Coppola G; Iapadre G; Operto FF; Verrotti A
    Drug Des Devel Ther; 2017; 11():643-657. PubMed ID: 28293101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brivaracetam for the treatment of epilepsy in adults.
    Mula M
    Expert Rev Neurother; 2014 Apr; 14(4):361-5. PubMed ID: 24625006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brivaracetam for the treatment of epilepsy.
    Schulze-Bonhage A
    Expert Opin Pharmacother; 2011 Aug; 12(12):1959-66. PubMed ID: 21682662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies.
    Moseley BD; Sperling MR; Asadi-Pooya AA; Diaz A; Elmouft S; Schiemann J; Whitesides J
    Epilepsy Res; 2016 Nov; 127():179-185. PubMed ID: 27608437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brivaracetam: A Review in Partial-Onset (Focal) Seizures in Patients with Epilepsy.
    Hoy SM
    CNS Drugs; 2016 Aug; 30(8):761-72. PubMed ID: 27503181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.
    Mumoli L; Palleria C; Gasparini S; Citraro R; Labate A; Ferlazzo E; Gambardella A; De Sarro G; Russo E
    Drug Des Devel Ther; 2015; 9():5719-25. PubMed ID: 26543353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models.
    Leclercq K; Matagne A; Provins L; Klitgaard H; Kaminski RM
    J Pharmacol Exp Ther; 2020 Jan; 372(1):11-20. PubMed ID: 31619464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: Two double-blind, randomized, multicenter, historical control, Phase III studies.
    Arnold S; Badalamenti V; Diaz A; Gasalla T; McShea C; Whitesides J; Fakhoury T
    Epilepsy Res; 2018 Mar; 141():73-82. PubMed ID: 29486396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
    Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures.
    Schoemaker R; Wade JR; Stockis A
    J Clin Pharmacol; 2016 Dec; 56(12):1591-1602. PubMed ID: 27146213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures.
    Schoemaker R; Wade JR; D'Souza J; Stockis A
    Epilepsy Res; 2017 Nov; 137():95-100. PubMed ID: 28982069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.